Reports
The following list of reports reflects the latest in findings and outcomes in medical research as presented at major medical meetings and published peer-reviewed medical journals. In this section you can view reports from important congresses as well as summaries of some recently published journal articles. Please let us know if you have a particular area of interest you would like to see covered.
PRIORITY PRESS - 76th Annual Meeting of the American College of Rheumatology (ACR)
Protection Against Radiologic Progression in Rheumatoid Arthritis with JAK Inhibition Appears Similar to IV Biologics
Washington, DC / November 10-14, 2012
Washington, DC - Oral agents that target intracellular pathways of inflammation are showing remarkable similarities to injectable monoclonal antibodies in the control of rheumatoid arthritis (RA). Along with phase III data supporting the...
MEDICAL FRONTIERS - 2012 Annual European Congress of Rheumatology (EULAR)
Oral Biologics Gain Attention as Safety Data Catch Up with Efficacy Data in Rheumatoid Arthritis Control
Berlin, Germany / June 6-9, 2012
Berlin - The potential to target the inflammatory cascade with oral rather than injectable targeted therapies in rheumatoid arthritis (RA) remains strong, based on studies evaluating agents with different mechanisms that were presented at...
PRIORITY PRESS - 2012 Annual European Congress of Rheumatology (EULAR)
Progress in Oral Biologics for Rheumatoid Arthritis
Berlin, Germany / June 6-9, 2012
Berlin - Oral therapies for rheumatoid arthritis that target very specific molecular steps in the inflammatory pathway have reached phase III trials. The data generated from these trials indicate that the anti-inflammatory activity of...
PRIORITY PRESS - Annual European Congress of Rheumatology (EULAR)
Potential Sequence of TNF Inhibitors in Rheumatoid Arthritis and Evidence for Staying in Class Before Switching Mechanisms
Berlin, Germany / June 6-9, 2012
Berlin - Approximately 30% of patients with rheumatoid arthritis (RA) treated with a tumour necrosis factor (TNF) inhibitor will not have an adequate response. However, inadequate response on one of these agents does not predict failure on...
PHYSICIAN PERSPECTIVE - Viewpoint based on presentations from the Annual Meeting of the Canadian Rheumatology Association
The Role of Biologics in Psoriatic Arthritis Disease Control
Victoria, British Columbia / March 28-31, 2012
Reviewed and edited by: Majed M. Khraishi, MB, BSc, FRCPCMedical Director (Rheumatology)Nexus Clinical ResearchClinical Professor of Medicine (Rheumatology)Memorial University of NewfoundlandSt. John’s, Newfoundland &...
PRIORITY PRESS - 75th Annual Meeting of the American College of Rheumatology
Non-TNF Inhibitor Biologics: Expanding Opportunities for Rheumatoid Arthritis Control
Chicago, Illinois / November 5-9, 2011
Chicago - Led by TNF inhibitors, biologics addressing a variety of mediators of inflammation, including other cytokines, as well as enzymatic pathways in the inflammatory response, have demonstrated unprecedented rates of control in...
PRIORITY PRESS - 75th Annual Meeting of the American College of Rheumatology
Novel Oral Inhibitors of Select Enzymatic Pathways in Rheumatoid Arthritis Inflammation
Chicago, Illinois / November 5-9, 2011
Chicago - Small-molecule inhibitors of enzymatic pathways that control inflammation in rheumatoid arthritis (RA) are advancing rapidly in clinical trials and are expected to generate the next major evolution in targeted therapy. The most...
MEDICAL FRONTIERS - 75th Annual Meeting of the American College of Rheumatology
Sequencing Biologic Therapeutic Strategies in Rheumatoid Diseases
Chicago, Illinois / November 5-9, 2011
Chicago - By preventing tissue damage caused by inflammation, TNF inhibitors are changing the natural history of joint diseases and other autoimmune processes. At the ACR 2011 meeting, substantial data and discussion were devoted to the...
PRIORITY PRESS - 75th Annual Meeting of the American College of Rheumatology
Interleukin-1 Inhibitors in Specific Rheumatoid Diseases
Chicago, Illinois / November 5-9, 2011
Chicago - Small-molecule inhibitors of enzymatic pathways that control inflammation in rheumatoid arthritis (RA) are advancing rapidly in clinical trials and are expected to generate the next major evolution in targeted therapy. The most...